Jove
Visualize
Contact Us

Related Experiment Videos

Interferon-beta1a treatment for multiple sclerosis.

Magnhild Sandberg-Wollheim1

  • 1Department of Neurology, University Hospital, Lund, Sweden. Magnhild.Sandberg@neurol.lu.se

Expert Review of Neurotherapeutics
|April 28, 2005
PubMed
Summary

Multiple sclerosis (MS) is a common neurologic disability in young adults, but its cause remains unknown. Current treatments, like interferon-beta, offer modest short-term benefits, with long-term efficacy and repair goals still distant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

International journal of MS care·2018
Same author

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2017
Same author

Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes.

Multiple sclerosis (Houndmills, Basingstoke, England)·2013
Same author

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.

Multiple sclerosis (Houndmills, Basingstoke, England)·2011
Same author

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Annals of neurology·2011
Same author

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.

Therapeutic advances in neurological disorders·2011
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Central Nervous System (CNS) Inflammation

Background:

  • Multiple sclerosis (MS) is a leading cause of neurologic disability in young adults.
  • The exact cause of MS is unknown, involving environmental factors and genetic susceptibility.
  • Current treatments for MS are unsatisfactory, with uncertain prognoses.

Purpose of the Study:

  • To review the current understanding of multiple sclerosis etiology and prognosis.
  • To evaluate the efficacy and limitations of available MS treatments, particularly interferon-beta.
  • To discuss unresolved issues regarding long-term treatment effects and disease modification.

Main Methods:

  • Review of existing literature on multiple sclerosis.
  • Analysis of data from large treatment trials of interferon-beta.
  • Discussion of unresolved clinical and research questions in MS management.

Main Results:

  • Interferon-beta is the most common MS therapy, with documented short-term efficacy.
  • Treatment effects of interferon-beta are modest, and long-term benefits are uncertain.
  • Key unresolved issues include effects on secondary-progressive MS, neutralizing antibodies, and brain atrophy.

Conclusions:

  • Despite recent advances, effective long-term treatments to prevent disability and promote repair in MS are still needed.
  • Further research is required to address the limitations of current therapies like interferon-beta.
  • Understanding the complex interplay of genetic and environmental factors is crucial for future MS therapies.

Related Experiment Videos